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Cancer biomarkersDNAmethylation at CpG sites is an epigeneticmechanism that regulates cellular gene expression. In cancer cells,
aberrant methylation is correlated with the abnormalities in expression of genes that are known to be involved in
the particular characteristics of cancer cells such as proliferation, apoptosis, migration or invasion. During the past
30 years, accumulating data have deﬁnitely convinced the scientiﬁc community that ion channels are involved in
cancerogenesis and cancer properties. As they are situated at the cell surface, they might be prime targets in the
development of new therapeutic strategies besides their potential use as prognostic factors. Despite the progress
in our understanding of the remodeling of ion channels in cancer cells, the molecular mechanisms underlying
their over- or down-expression remained enigmatic. In this review, we aimed to summarize the available data
on gene promoter methylation of ion channels and to investigate their clinical signiﬁcance as novel biomarkers in
cancer. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
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Ahidouch).1. Introduction
In humans, tumorigenesis is a process whose steps are the conse-
quences of genetic alterations that will result in the transformation of
normal cells into malignant derived cells. Progressive cell transforma-
tion implies changes in numerous cell signaling occurrences that
ultimately lead to the acquisition by cancer cells of speciﬁc capabilities
such as uncontrolled proliferation, resistance to apoptosis and up-
regulatedmigration and invasion that aremainly acquired after changes
2622 H. Ouadid-Ahidouch et al. / Biochimica et Biophysica Acta 1848 (2015) 2621–2628in the cell genome [1]. Even though mutation of speciﬁc genes can
explain cell transformation from normal to cancer cell, epigenetic mech-
anisms, such as changes in DNAmethylation status can also be involved.
Among all genes that have been reported to be targets of such regulatory
mechanisms, genes encoding ion channels are potential targets. This lat-
ter point is especially important since an increased number of studies
clearly show that the dysregulation of ion channel expression is involved
in tumorigenesis and cancer cell properties such as proliferation, cell
survival and invasiveness or resistance to therapies [2–5]. Ion channels
have also been used as diagnostic and prognostic biomarkers of cancer
[6,7] and have also been used for targeted therapy [8,9]. As their expres-
sion is up or down regulated in cancer and as actively transcribed genes
are generally associated with promoter hypomethylation and inactive
promoters with DNA hypermethylation, the DNA methylation status of
some ion channel gene promoters has been investigated in cancer. This
review summarizes our current knowledge regarding the implication of
themethylation process of various ion channel genes in different cancers.
2. DNA methylation
Methylation consists of the addition of a methyl group on a
nucleotidic base of the DNA through the action of the DNAmethyltrans-
ferase enzymes (DNMTs) [10]. In Eucaryotes, only cytosine belonging to
CG dinucleotides can be methylated, in the 5′ position, leading to the
formation of 5-methylcytosine. These CG dinucleotides are also named
CpG, in reference to the phosphodiester bond between the cytosine
and the guanine. These CpG are distributed in islands, particularly con-
centrated in promoter regions of genes. CpG islands have a frequency of
CpG dinucleotides approximately ﬁve times greater than the genome
and represent 1–2% of the whole genome. In human, about 50–70%
of genes have a promoter rich in CpG islands [11,12]. The methylation
of CpG islands plays an important role in gene regulation, and usually
represses their transcription.
Methylation patterns are established during the ﬁrst cell divisions
after fertilization, once the parental DNA has been demethylated. Once
established, at each cell division, the methylation patterns are faithfully
transmitted to daughter cells. However, methylation is proven to
decline with age [13]. Some CpG islands undergo differential allelic
methylation. This is the case of the CpG islands localized on the X chro-
mosomes in females that aremethylated on the inactiveX chromosome.
This is also the case of many imprinted genes.
2.1. DNA methylation in cancer
Carcinogenesis requiresmultiple genetic alterations that either drive
cellular division (ampliﬁcation of oncogenes) or remove checkpoints
regulating this process in normal cells (inactivation of tumor suppressor
genes), leading to the uncontrolled growth of cells, without consideration
for the organism's need. In the past decades, many studies have shown
that epigenetic changes, including DNA methylation modiﬁcations, also
play a role in cancer development and progression [14]. From these ob-
servations, at least three major mechanisms by which CpG methylation
can contribute to the oncogenesis can be distinguished. The ﬁrst is the
hypomethylation of the cancer genome that can lead to the activation
of putative oncogenes, and enhances the genome instability. The loss of
methylation can be localized to particular types of repetitive elements
or to chromosomal domains [15]. The second is the focal hypermethyla-
tion of the promoters of tumor suppressor genes that inactivate their
transcription. This mechanism is highly prevalent and well illustrated
by the hypermethylation of the promoters of RB1 in retinoblastoma
[16], of MLH1 in colon cancer [17,18], and of BRCA1 in breast cancer
[19]. The third is direct mutagenesis, by the fact that methylated CpG
sites are hotspots for C to T transition mutations caused by spontaneous
hydrolytic deamination. Additionally, methylation of CpG islands also
promotes the binding of chemical carcinogens, and increases the rate of
UV-induced mutations [20].3. Hypermethylation of ion channel gene promoter and cancer
(Table 1)
3.1. Chloride channels
The CFTR (cystic ﬁbrosis transmembrane conductance regulator) is a
member of the ATP-binding cassette transporter family whose promot-
er methylation is generally associated with gene inactivation whereas
its expression is correlated with promoter unmethylation [21]. Indeed,
the CFTR is one of the CpG-rich promoters where the CpG sites are not
methylated in high and low CFTR-expressing cell lines. However, the
CpG sites are partially or completely methylated in the very low or
non-CFTR-expressing cell lines [21,22].
In cancer, the CFTR gene is reported to be frequently hypermethylated
in bladder cancer [23], in hepatocellular carcinoma [24,25], and in breast
cancer [26]. Recently Son et al. [27] has reported aberrant methylation
associated with CFTR downregulation in 139 samples from patients
with non-small cell lung cancer (NSCLC). Otherwise, the methylation of
the CFTR promoterwas related to a loss of gene expression and treatment
of A549 lung cancer cells by the demethylating agent 5-aza-2′-
deoxycytidine (5-Aza-dC) induces the re-expression of CFTR mRNA in
these cells which support the role of methylation as a mechanism of
CFTR gene inactivation.
In agreement with this ascertainment a correlation between the
degree of CpG methylation and the level of CLCA2 (calcium-activated
chloride channel) gene expressionwas reported in breast cancer tissues
and cell lines [28]. By using bisulﬁte DNA sequencing, they demonstrate
that the promoter region is hypermethylated in tumor cells that show
no or low CLCA2 expression, while, CLCA2-promoter methylation is
not detected in samples, derived from normal breast tissue, as well as
in normal epithelial breast cells (MCF-10A). Moreover, methylation of
the CLCA2 promoter region was reduced in cell lines treated with
5-Aza-dC agent, while the expression of CLCA2 RNA was restored. This
property, as well as the ensuing consequences, leads Li et al., [28] to
suggest CLCA2 as a tumor suppressor gene in breast cancer. In full agree-
ment with this consideration, it was shown that transfecting breast
cancer cell lines (MDA-MB-435 and MDA-MB-231) with CLCA2 under
the control of a promoter resistant to inhibitory hypermethylation
reduces migration and invasion, but failed to change growth rate or
anchorage-independent growth of these cells in soft and hard agar
[29]. Alongside, nudemice injected withMDA-MB-231 cells transfected
with CLCA2 produce few tumors and exhibit either reduced tumor
size or no lung tumors when compared with MDA-MB-231 control
inoculated mice [29]. Moreover, the high-level expression of mCLCA2
correlated closely with the onset of apoptosis [30]. Altogether, these
data suggest that loss of CLCA2 expression in human breast cancer is
likely associated with tumorigenicity [29].
3.2. Calcium channels
Basically, calcium channels are implicated in many biological pro-
cesses potentially relevant to themalignant process including prolifera-
tion, apoptosis and metastasis [31,32]. Both CACNA1G (T-type Ca2+
channel) and CACNA2D3 (calcium channel regulatory subunit α2δ-3)
have numerous properties consistent with tumor and/or metastasis
suppressor function as demonstrated by their ectopic expression that
inhibits breast and gastric cell growth, whereas the knockdown using
inhibitory RNA or pharmacological tools leads to increased gastric and
breast cancer cell proliferation [33,34], and breast cancer cell apoptosis
[34]. Further evidences supporting the role of CACNA2D3 as a tumor
suppressor gene in lung cancer, renal cancer, neuroblastoma and osteo-
sarcoma have been reported [35–39].
Hypermethylation of CACNA1G is detected in various human primary
tumors: colorectal cancers (≈35%), gastric cancers (≈25%), acute mye-
logenous leukemia cases (≈13%) [40], and pancreatic adenocarcinoma
(≈16%) [41]. It is proposed that inactivation of CACNA1G may play a
Table 1
Aberrant methylation of ion channel gene promoter in cancer.
Gene symbol Gene name Tumor type Methylation
status
Correlation with clinical
parameters
References
CFTR Cystic Fibrosis Transmembrane
Conductance Regulator (ATP-Binding
Cassette Sub-Family C, Member 7)
Lung cancer
Non-small cell lung
cancer (tissue and cell lines)
Hyper methylation • More frequently observed in squamous
carcinomas than adenocarcinomas
• Associated with poor survival among
younger patients
[27]
Bladder cancer Hyper methylation • Marker of bladder cancer [23]
Hepatocellular carcinoma
(tissue samples)
Hyper methylation n.d. [24]
Hepatocellular carcinoma
(tissue samples)
Hyper methylation • Potential marker of well-differentiated
hepatocellular carcinoma
[25]
Breast cancer
MCF-7 cell line
Hypermethylation n.d. [26]
CLCA2 Chloride Channel Accessory 2 Breast cancer Hyper methylation n.d. [28]
CACNA1G Calcium channel, voltage-dependent,
T type, alpha 1G subunit (Cav3.1)
Colorectal cancer
Colorectal adenoma
Gastric cancer
Acute myelogenous leukemia
Hypermethylation
Hypermethylation
Hypermethylation
Hypermethylation
• Correlation with methylation of p16 [40]
Pancreatic adenocarcinoma Hypermethylation n.d. [41]
CACNB2 Calcium channel, voltage-dependent,
Beta 2 subunit
Esophageal adenocarcinoma Hypermethylation [53]
CACNA2D3 Calcium channel, voltage-dependent,
Alpha 2/Delta Subunit 3
Gastric cancer diffuse type
Intestinal type
Hypermethylation
Hypermethylation
• Correlation with poorer outcome [33]
Breast cancer Hypermethylation • Frequently methylated in breast cancer
that metastasized to the CNS
• Association with increased risk of recurrence,
particularly at visceral sites of liver and lung
[42]
Gastric cancer Hypermethylation • Correlation with physical activity [56]
KCNA3 Voltage-gated potassium channel,
shaker related subfamily,
member 3 (Kv1.3)
Breast cancer Hypermethylation • Poor differentiation (SBR histological grade III) [45]
Pancreatic cancer Hypermethylation • Associated with poor patient survival [44]
Lung, ovarian, kidney, prostate
colon cancer
Hypermethylation [46]
KCNH2 Potassium voltage-gated channel,
Subfamily H (Eag-related),
Member 2 (HERG, KV11.1)
Ovarian cancer Hypermethylation • A good prognostic marker in ovarian cancer [48]
Melanoma Hypermethylation n.d. [47]
KCNH5 Potassium voltage-gated channel,
Subfamily H (Eag-related),
Member 2 (Kv10.2, EAG2)
Lung cancer Hypermethylation n.d. [52]
Esophageal adenocarcinoma Hypermethylation n.d. [53]
Non-small cell lung cancer Hypermethylation • More frequent in adenocarcinomas
compared to squamous cell carcinomas
[54]
KCNH5 & KCNH8 Potassium voltage-gated channel,
Subfamily H (Eag-related),
Member 5 (Kv10.2, EAG2) & 8
(ELK, ELK1, elk3, Kv12.1)
Non-small cell lung cancer Hypermethylation • More frequent in females compared to males [54]
KCNN2, KCNIP1,
KCNQ5, KCNK9,
KCNE2, KCNG1,
KCNA6, KCNV1,
KCNAB3, KCNJ15,
KCNJ8
K+ channels (KCN family) Esophageal adenocarcinoma Hypermethylation n.d. [53]
CACNA1H α1H T type Ca2+ channel (Cav3.2) Adult T-cell leukemia Hypomethylation n.d. [74,75]
KCNH5 Potassium voltage-gated channel,
Subfamily H (Eag-related),
Member 2 (Kv10.2, EAG2)
Melanoma Hypomethylation [78]
KCNN4 Potassium intermediate conductance
calcium-activated channel,
subfamily N, member 4
(KCa3.1, SK4…)
Lung cancer Hypomethylation • Strong indicator of poor prognosis in
lung cancer
[98]
KCNQ1OT1 KCNQ1 opposite strand/antisense
transcript 1
Adrenocortical adenomas
and carcinomas
Hypomethylation n.d. [99]
Aquaporin 1 Aquaporin 1 (water channel protein) Salivary gland adenoid
cystic carcinoma
Hypomethylation n.d. [77]
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that potentially affects, at a time, cell proliferation and apoptosis [40].
Hypermethylation of CACNA2D3 is concomitant with its down-
regulated expression in breast cancer cell lines, primary cancers and
metastatic lesion tumors [42], as well as in gastric cell lines and tissue
samples [33]. In contrast, the CpG islands are unmethylated in normal
gastric and breast tissues as well as in corresponding normal cell lines.
In this case as well, 5-Aza-dC upregulates the expression of CACNA2D3
in both breast and gastric cancer cells that exhibit CpG island methyla-
tion but fails to affect cells lackingmethylation.Moreover, in vitro exog-
enous CACNA2D3 expression inhibits cell growth and adhesion and upregulates p21 and p27 expression in gastric cancer cell lines with
inverse effects with CACNA2D3 small interfering RNA treatment [33].
These results are consistentwithmethylation-dependent transcription-
al silencing being themechanistic basis of CACNA2D3 downregulation in
breast and gastric cancer.
3.3. K+ channels
Potassium channels have been reported to play various roles in can-
cer progression aswell as cell proliferation, apoptosis,migration, and in-
vasion during metastasis [2,4,5,43].
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and its association with the decrease of the expression of Kv1.3 channel
were ﬁrst published in breast and pancreas adenocarcinomas [44,45].
More recently, KCNA3 promoter hypermethylation was also identiﬁed
as one of the most prevalent events in tumorigenesis affecting various
tumor types including lung, ovarian, kidney, prostate and colon [46]. Re-
cently, an inverse relationship between methylation and expression of
KCNH2 (hERG1, Kv11.1) was also found to be associated with clear-
cell ovarian cancer (171 tissue samples) and lymphoma, highlighting
the well-established role of CpG island hypermethylation on repression
of gene expression [47,48]. Given that overexpression of hERG1
promotes proliferation, migration and metastasis in ovarian cancer
[49,50], it was suggested that loss of expression of hERG1 by methyla-
tion could be a good prognostic marker in ovarian cancer [48].
The KCNH5 gene (also known as EAG2 or Kv10.2), encodes an EAG
voltage-gated potassium channel that is involved in the regulation of
cell cycle and proliferation [51]. The methylation of KCNH5 gene was
also identiﬁed in lung cancer [52]. KCNH5 is respectively methylated
and hypermethylated in 80% and53% of NSCLC tissues [52]. Interestingly,
when KCNH5 gene promoter is methylated in cancer tissue, a slight
methylation (14%) is found in the adjacent noncancerous lung tissues.
On the other hand, KCNH5 is hypermethylated in cancerous tissues and
no methylation is observed in noncancerous tissues [52]. Furthermore,
hypermethylated CpG sites of KCN genes, that encode for a large number
of K+ channel families (Table 1), have also been reported in esophageal
carcinoma [53].
3.4. Link between ion channel promoter aberrant methylation and clinical
outcomes in cancer (Table 1)
To our knowledge, there are few studies that address a possible
link between ion channel promoter aberrant methylation and different
clinical outcomes in cancer (Table 1).
A study performed on a cohort of 139 non-small cell lung cancer
(NSCLC) samples, among which were 60 squamous cell carcinoma
(SCC) and 79 adenocarcinoma (AC), and the matched non-malignant
lung tissue samples shows methylation of CpG islands in the CFTR
gene promoter in 30.2% (vs. 18.7%) of the studied tissue samples. The
CFTR methylation is associated with loss of CFTR gene expression and
its frequency is signiﬁcantly higher in tissue samples from SCC than
AC [27].
Regarding the survival of patientswithNSCLC, there is no correlation
between promotermethylation of the CFTR gene and the patient's prog-
nosis. However, CFTRmethylation is associatedwith signiﬁcantly poorer
survival among younger patients vs. elderly patients. The prognostic
and predictive factors identiﬁed in this studymay be useful in consider-
ations of which patients are likely to beneﬁt from adjuvant therapy [27].
Another study, conducted on samples from patients with bladder
cancer, highlights a strongmethylation proﬁle of an 11-gene set includ-
ing CFTR (which ranks second) in urine sediments. This makes these
genes and the CFTR in particular a sensitive and speciﬁc tool for detec-
tion of bladder cancer [23].
The methylation of KCNA3 (Kv1.3 K+ channel) is correlated to SBR
histological grade III in breast cancer [45]. Indeed, the methylation of
the KCNA3 promoter is associated with poor differentiation inasmuch
as 54% of methylation is found in grade III tumors versus only 13% in
grade I tumors. In grade II tumors, Kv1.3 gene promoter methylation
is observed in 52% of the cases. Otherwise, no difference was observed
between methylated and unmethylated tumors in terms of lymph
node status, estrogen and progesterone receptor expression, ErbB2
expression and expression of the Ki67 proliferation index [45]. The
same authors have pointed out an association between Kv1.3 hyperme-
thylation and the survival rate in patients with pancreatic cancer,
although the association did not reach statistical signiﬁcance [44].
Methylation patterns of KCNH5 (Kv10.2, EAG2) and KCNH8 (ELK,
ELK1, elk3, Kv12.1) varied depending on histological type of lung cancer[54]. Both gene promoters are hypermethylated in non-bronchoalveolar
adenocarcinomas compared to squamous cell carcinomas. Furthermore,
both KCNH8 and KCNH5 hypermethylation was more frequent in fe-
males compared to males [54]. However, this study, performed on a
small sample, deserves to be checkedwith a greater number of samples.
In a study on gastric cancer, CACNA2D3 (calcium channel, voltage-
dependent, alpha 2/delta subunit 3) is proposed to have tumor suppres-
sive functions [33]. Indeed, its overexpression in CACNA2D3-positive
HEK-293T and CACNA2D3-negative NUGC4 cell lines signiﬁcantly
inhibits cell growth of transfected cells versus controls. It also
inhibits cell adhesion and upregulates p21 and p27 expression in both
transfected cell lines. In this regard, it is reported that patients with
gastric cancerwhich donot express p27 protein haveworse clinical out-
comes than patients with intact p27 expression [55] suggesting that
CACNA2D3-negative gastric cancers are suspected to bemore aggressive
than positive ones with respect to p27 expression rate. Otherwise,
survival of patients with CACNA2D3-methylated gastric cancers is
signiﬁcantly shorter than that of patients whose CACNA2D3 is non-
methylated. These ﬁndings support the proposal that methylation of
CACNA2D3 is a useful prognostic marker for patients having advanced
gastric cancer.
Besides, CACNA2D3 methylation status is conversely correlated to
physical activity (i.e., more frequently found in gastric carcinoma
patients having nophysical activity than in thosewith physical activity).
As a consequence of this, Yuasa et al. [56] hypothesize that some life-
style factors may inﬂuence gastric cancer development.
Recently, CACNA2D3 CpG island methylation has been investigated
in central nervous system metastases derived from primary breast
carcinomas [42]. The results show that CACNA2D3 transcripts are
regulated, in breast cancer cell lines, through the DNA methylation in
the promoter-associated CpG islands. This methylation is upregulated
by pharmacological demethylation using Azacytidine. Moreover, this
promoter-methylation is regularly observed in breast cancer that
metastasizes to the central nervous system. Furthermore, in a large
series of 100 primary breast carcinoma samples, an association is point-
ed out between methylation and increased risk of cancer recurrence,
particularly at visceral sites of liver and lung. This may contribute to
breast cancer metastatic phenotype [42].
3.5. Other channels and transporters
Many studies have shown that other channels and transporters
encoding genes could be the target of methylation or demethylation
processes and involved in cancer or cell transformation. Thus, a study
from Xu and collaborators described, in a genome-wide methylation
analysis, the methylation of several genes in esophageal adenocarcino-
ma [53]. Among all of these genes, they reported genes that have been
described to be methylated for a long time but also new and unusually
frequent hypermethylated genes such as membrane transporter and
ion channel genes. Thus, they reported the hypermethylation of
SLC18A3 and SLC6A2, a vesicular acetylcholine (Ach) transporter and a
norepinephrine transporter, respectively. More interestingly, they
reported the hypermethylation of CACNB2 (gene encoding for the beta
2 subtype of voltage-dependent Ca2+ channel), and CHRNA3 (gene
encoding for the neuronal Ach receptor α3 subunit).
Xia et al. [57] reported that ASIC2 (the gene that encodes the Acid
Sensing Ion Channel 2) is also a potential target formethylation. Indeed,
they showed that its differential regulation of expression occurs
between high-grade glial-derived tumor cells and normal astrocytes.
In one study, they showed that ASIC2 mRNA is absent in the majority
of glioma cells [58] whereas both ASIC1 and ASIC2mRNAs are present
in both normal brain tissue or from low-grade or benign tumors. By
the use of methylation-speciﬁc PCR experiments, they revealed that
four glioma cell lines which do not express ASIC2 or express a very
low level of ASIC2 have DNA methylation in the CpG island of the pro-
moter. In the same way, they showed that in 12 freshly resected
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ylation and that ASIC2 gene expression is mostly absent or at low levels.
It has been shown that ENSA (endosulﬁne alpha),which is a ligand of
sulfonylurea receptor that is coupled to KATP channels involved in insu-
lin release process, is a bivalent gene in mesenchymal stem cells that is
involved in cell differentiation and transformation [59,60]. Interestingly,
in breast cancer cell lines, ENSAmethylation state changes in response
to environmental signals such as changes in estrogen [61]. In a
recent work, Chen et al. [62] showed a deregulated ENSAmethylation
in liver and breast cancers. Their methylation state was opposite
to each other, indicating lineage-speciﬁc methylation changes.
Indeed, ENSA promoter was hypomethylated in liver cancer but was
hypermethylated in breast cancer. They determined that ENSA expres-
sion correlates with attenuated tumor propagation in liver cancer and
that ENSA hypomethylation in liver cancer usually indicates gain of
ENSA function in tumorigenesis. They showed also that the DNA meth-
ylation inhibitor (5-Aza-dC) was able to induce an elevation of ENSA
expression and that ENSA suppressed the hepatic tumor growth in
cultured cells and in mice xenograft models through an interaction
with microtubule-associated serine/threonine-protein kinase-like.
They speculated that silenced ENSA function might be essential for
liver cancer initiating cells but not necessary for tumor expansion in
liver cancer.
3.6. Ionotropic receptors in cancer (Table 2)
The ionotropic glutamate receptors (N-methyl-D-aspartate
receptors (NMDARs)) are oligomeric protein complexes that form ion
channels in the plasma membrane that enable ion ﬂuxes (e.g., Ca2+)
known to be crucial for cellular properties such as synaptic transmis-
sion, muscular cell contraction or cancer cell migration and survival
[63,64]. Recently, several studies highlight their role in cancer cell
growth and propose them as potential therapeutic targets [65–67].
High methylation of GRIN2B and GRIN2A (genes that encode
NMDAR2B and -2A respectively) are reported to be tumor suppressors
in different carcinomas. GRIN2B is highly methylated in esophageal,
head and neck squamous carcinomas, and gastric cancer [68,69]. The
methylation of GRIN2B is associated with the silencing of NMDAR2B
expression. NMDAR2B expression is reactivated by a treatment by a
well-known DNA methyltransferase inhibitor (5-Aza-dC). Moreover,
ectopic expression of NMDAR2B in cells that do not express NMDAR2B
leads to drastic cell apoptosis in esophageal cancer and to a decrease of
colony gastric cancer forming ability. GRIN2B is either proposed as a
high cancer frequency biomarker [68] or may serve as an important
molecular marker in serum/plasma DNA for early cancer detection
and monitoring [69]. GRIN2B has also recently been found to be highly
methylated in lung cancer cell lines and cancer tissues from adenocarci-
nomas and large cell carcinomas where it is upregulated following the
use of 5-Aza-dC [70]. Interestingly, GRIN2B methylation is associated
with a better prognosis in squamous cell carcinoma [70].Table 2
Hypermethylation of glutamate receptor, ionotropic, NMDAR (2A and 2B) and Kainate 2.
Gene symbol Gene name Tumor type
GRIN2B Glutamate receptor, ionotropic,
N-methyl D-aspartate 2B (NMDAR2B)
Lung (adenocarci
(adeno-squamou
Squamous carcino
Esophageal and h
carcinomas(ESCC
Esophageal squam
cancer cell lines
GRIN2A Glutamate receptor, ionotropic, N-methyl
D-aspartate 2A (NMDAR2A)
Colorectal cancer
GRIK2 Glutamate receptor, inotropic, kainate 2 (GLUR6) Gastric cancer celOn the other hand, GRIN2A (the gene that encodes NMDA2A)
was studied in colorectal cancer (CRC) cell lines and Human CRC
tissues versus corresponding normal adjacent mucosa [71]. GRIN2A is
hypermethylated in 100% of the studied cancer cell lines and is
reactivated using 5-Aza-dC. Moreover, NMDR2A shows tumor suppres-
sive activity as assessed in transfected-HTC116 cells which is found to
regulate the early stage of apoptosis. These results have led Kim et al.
[71] to propose GRIN2A as a potential diagnostic and therapeutic target
molecular marker for colorectal cancer.
Finally, GRIK2, which encodes Glutamate Receptor, Ionotropic,
Kainate 2 (GLUR6), has also been reported as a tumor-suppressor
in gastric cancer [72]. GRIK2 hypermethylation in gastric cancer is asso-
ciated with loss of its gene expression. Moreover, GRIK2-expressing
gastric cancer cell lines are both unable to migrate and fail to form
colonies. These results allow for the proposal of GRIK2 as a potential
tumor marker for gastric cancer.4. Hypomethylation of ion channel gene promoter and cancer
(Table 1)
Because cancer-linked DNA hypomethylation might occur early
in oncogenesis, very few studies reported a correlation between
hypomethylated channels and tumoral processes.
The ﬁrst related one was CACNA1H gene (α1H T type Ca2+ channel)
is normally transcribed in kidney and heart [73]. Authors showed
that in CACNA1H gene, CpG sites in both the 5′ and 3′ regions were
hypomethylated in Adult T-cell Leukemia, and CACNA1H genewas aber-
rantly transcribed, suggesting a link between DNA hypomethylation
and the aberrant transcription [74]. It has been reported that antago-
nists of T-type Ca2+ channels inhibited cell proliferation [75] suggesting
that its aberrant expression is associated with cell proliferation [74].
Aquaporins (AQPs) arewater channels known to be formed by iden-
tical subunit proteins. Among isoforms of aquaporins, AQP1 is expressed
in different human cancers where it is involved both in cell proliferation
and migration [76].
In primary Adenoid Cystic Carcinoma (ACC) tissues, AQP1 is
both hypomethylated and overexpressed at mRNA and protein levels
when compared to normal salivary tissue [77]. Interestingly, treatment
by demethylating agents of ACC-derived SACC83 cell line, in which
AQP1 is methylated and exhibits low expression, induces AQP1 re-
expression agreeing for an epigenetical regulation of AQP1 expression.
Moreover, transient expression of AQP1 leads these cells to proliferate
and form large size colonies versus control cells. Furthermore, silencing
AQP1, in non-small cell lung carcinoma cell lines which show high AQP1
expression, leads to the inhibition of cell growth. On the basis that
silencing of AQP1 inhibited cancer cell growth and that the expression
of AQP1 was regulated by promoter demethylation, AQP1 is proposed
as a potential novel therapeutic target and a promising oncogene candi-
date in Adenoid Cystic Carcinoma [77].Correlation with clinical parameters References
noma large cell carcinoma)
s cell carcinoma) cell lines
ma
No correlation among gender, age,
smoking, histological type, or stage
Better survival
Better prognosis
[70]
ead and neck squamous cell
) cell lines,
n.d. [68]
ous cell carcinoma gastric n.d. [69]
cell lines n.d. [71]
l lines n.d. [72]
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of the human placental-speciﬁc KCNH5 promoter, a retrotransposon-
derived transcript of the EAG voltage-gated potassium channel gene,
is frequently associated with KCNH5 expression in melanoma cells.
Since EAG and KCNH5 have been involved in cell cycle regulation, prolif-
eration and tumor progression in cancer [79,80], the methylation state
of this gene appears as an interesting hallmark in melanoma [78].
Moreover, at the last meeting of the German Physiological Society,
Schwab's team demonstrated that KCa3.1 channel gene (KCNN4) pro-
moter is hypomethylated in an aggressive non-small cell lung carcino-
ma cell line and in patient samples [81]. The loss of DNA methylation
of the KCNN4 promoter was associated with an increased KCa3.1
channel expression and function, both ﬁndings being strong indicators
of poor prognosis in lung cancer.
5. Potential clinical aspects and pharmacological tools
Aberrant promoter methylation has been described for several
genes in various malignancies and thewide spectrum of genes involved
suggest that speciﬁc tumors may have their own distinct methylation
proﬁle [82,83].
Studies on aberrant methylation of channel-related genes are
increasingly emerging. The available data from recent studies in several
types of cancer show that aberrant methylation of ion channels is a
cancer-speciﬁc ﬁnding, since it is signiﬁcantly observed in cancer and
is not likely to be found in healthy control tissue. Moreover, a growing
body of evidence has conﬁrmed the correlation of CFTR, KCNA3,
CACNA2D3hypermethylation andKCNN4hypomethylationwith several
clinicopathological parameters, including advanced disease (poor
differentiation), recurrence, and disease-speciﬁc survival. However,
more prospective studies are needed to afﬁrm the clinical use of ion
channel methylation status (hypermethylation, hypomethylation) as a
fully independent prognostic marker in larger groups of patients.
As presented in this review, destabilization of DNAmethylation pat-
terns (hypermethylation or hypomethylation) increases tumorigenesis.
Such epigenetic events have been used for treatment, by increasing or
decreasing methylation processes [84].
For example, a therapeutic strategy blocking DNA methylation
with 5-azacytidine [85] and 5-aza-2′-deoxycitidine has been approved
by the Food and Drug Administration for treatment of preleukemicMethylation
Tumeur
suppressor
gene
silencing
Few or
non
expression
    of ion
channels
Ectopic expression
Demethylating agents
Re-expression of ion
channels
Decrease
proliferation
Inducti
apopt
A
B
Hypomethylation
Oncogenes
activation,
overexpression
of ion channels
Prolife
Fig. 1.Aberrant epigeneticmodiﬁcations of ion channels in cancer. A) During tumorigenesis, sile
Methylation-mediated silencing is reversed either upon treatment with DNA methyltransf
proliferation and metastasis aggressiveness and increase of apoptosis. B) Hypomethylation o
and progression of cancer.myelodysplastic syndrome [86]. In the 1980s, these compounds were
found to have hypomethylating activity after incorporation into the
DNA of actively replicating tumor cells [87,88]. They have since been
used in clinical trials for several forms of cancer [89]. In vitro investiga-
tions have demonstrated that these compounds may reverse abnormal
DNA methylation and eventually restore normal gene expression pro-
ﬁles in various cancer cell lines [90]. Nevertheless, it has been suggested
that the effects of chemotherapeutic agents inducing hypomethylation
may be beneﬁcial in the short-term, but theymay allow for progression
and recurrence from cancer cells that survive or are even enhanced by
DNA hypomethylation [91].
On the other hand, pharmacological tools inducingDNAmethylation
may be a beneﬁcial approach like for Glioblastoma Multiform patients
[92]. Indeed, temozolomide (TMZ) an oral alkylating agent has been
shown to exhibit great antitumor activity, by activatingmismatched re-
pairmechanisms andDNAdamage signaling pathways, leading to G2/M
cell cycle arrest and eventually to induction of cell death [92–94]. How-
ever, its use in the treatment of GlioblastomaMultiformwas limited due
to its insufﬁcient delivery across the blood–brain barrier and its
resistance to the drug. Interestingly, Ningaraj et al. [95] showed that in-
travenous administration of ATP-sensitive potassium channel activator
(minoxidil sulfate) increases TMZ delivery to brain tumors. At the
same time, they also demonstrated that co-infusion of a calcium-
dependent potassium (KCa3.1, SK4) channel agonist (NS-1619) with
TMZ and herceptin resulted in enhanced drug delivery to brain-tumor
cells [96]. In this context, KCa channel agonists may beneﬁt brain
tumor patients by increasing an anti-neoplastic agent's delivery to
brain tumors. This original combination has led to various studies that
use a mixed therapy approach where TMZ is combined with either
radiation therapy or other anti-cancer agents [97].
Althoughmethylation of ion channels is still a novel area of research
in oncology, the development of the ﬁeld might enable the identiﬁca-
tion of subgroups of patients with poor prognosis, who might require
a different therapeutic approach.
6. Conclusions
It is nowwidely recognized that epigenetic alterations are associated
with the process of neoplastic transformation. Epigenetic alterations of
ionic channel-related genes may contribute to carcinogenesis byProliferation
&
survival
Metastasis
&
aggressiveness
Poor
prognostic
markers?
on of
osis
Decrease
migration &
invasion
Epigenetic
therapies?
ration
Metastasis
&
aggressiveness
Poor
prognostic
markers?
ncing gene expression of ion channels is associatedwith their promoter hypermethylation.
erase inhibitors, or experimental re-expression of ion channels leading to decrease of
f ion channel gene promoter mediates oncogene activation leading to the development
2627H. Ouadid-Ahidouch et al. / Biochimica et Biophysica Acta 1848 (2015) 2621–2628regulating their expression (Fig. 1). Hypermethylation of ion channel
gene promoter is frequent in breast, lung, and gastric cancer and is asso-
ciated with loss of their expression. The restoration of their expression
by an ectopic expression, or a treatment by demethylating agents,
which inhibits cell proliferation, metastasis and increases apoptosis ar-
gues for their use as new potential therapeutic strategies for cancer
(Fig. 1A).
Hypomethylation of ion channel gene promoters is less frequent
than hypermethylation in cancer. Loss of DNA methylation in the pro-
moter region of certain ion channel genes (KCNN4, AQP1 and KCNH5)
has been reported in non-small cell lung cancer, Adenoid Cystic
Carcinoma, and melanoma that is associated with an increase of their
expression. Furthermore, ion channel gene promoter hypermethylation
as well as hypomethylation are strongly correlated with a poor progno-
sis, suggesting that both could potentially serve as a clinically useful
prognostic factor (Fig. 1).
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